Abstract
We investigated the propagation of population pharmacokinetic information across clinical studies by applying Bayesian techniques. The aim was to summarize the population pharmacokinetic estimates of a study in appropriate statistical distributions in order to use them as Bayesian priors in consequent population pharmacokinetic analyses. Various data sets of simulated and real clinical data were fitted with WinBUGS, with and without informative priors. The posterior estimates of fittings with non-informative priors were used to build parametric informative priors and the whole procedure was carried on in a consecutive manner. The posterior distributions of the fittings with informative priors where compared to those of the meta-analysis fittings of the respective combinations of data sets. Good agreement was found, for the simulated and experimental datasets when the populations were exchangeable, with the posterior distribution from the fittings with the prior to be nearly identical to the ones estimated with meta-analysis. However, when populations were not exchangeble an alternative parametric form for the prior, the natural conjugate prior, had to be used in order to have consistent results.
In conclusion, the results of a population pharmacokinetic analysis may be summarized in Bayesian prior distributions that can be used consecutively with other analyses. The procedure is an alternative to meta-analysis and gives comparable results. It has the advantage that it is faster than the meta-analysis, due to the large datasets used with the latter and can be performed when the data included in the prior are not actually available.
Similar content being viewed by others
References
A. Gelman JB. Carlin HS. Stern D.B. Rubin (1995) Bayesian Data Analysis Chapman & Hall London
A. Racine-Poon (1985) ArticleTitleA Bayesian approach to nonlinear random effects models Biometrics 41 1015–1023 Occurrence Handle4096913 Occurrence Handle1:STN:280:BimC28%2Fgslc%3D
A. Gelman F. Bois J. Jiang (1996) ArticleTitlePhysiological pharmacokinetic analysis using population modeling and informative prior distribution J. Am. Stat. Assoc. 91 1400–1412
Gamerman D., Smith A.F.M. (1996). Bayesian analysis of longitudinal data studies. In Bayesian Statistics 5, J. M Bernardo, Berger JO., A. P. Dawid and A. F. M. Smith, (eds), Oxford: University Press, Oxford, 1996, pp. 587–597
J. Wakefield (1996) ArticleTitleThe Bayesian analysis of population pharmacokinetic models J. Am. Stat. Assoc. 91 62–75
D.J. Lunn L.J. Aarons (1997) ArticleTitleMarkov Chain Monte Carlo techniques for studying interoccasion and intersubject variability: Application to pharmacokinetics data Appl Statist. 46 73–91
JE. Bennett JC. Wakefield L.F. Lacey (1997) ArticleTitleModeling of trough plasma bismuth concentrations J. Pharmacokinet Biopharm. 25 79–106 Occurrence Handle10.1023/A:1025771811143 Occurrence Handle9353695 Occurrence Handle1:CAS:528:DyaK2sXnt1Cmtrs%3D
J. Wakefield N. Rahman (2000) ArticleTitleThe combination of population pharmacokinetics studies Biometrics 56 263–270 Occurrence Handle10.1111/j.0006-341X.2000.00263.x Occurrence Handle10783805 Occurrence Handle1:STN:280:DC%2BD3c3ks1agtw%3D%3D
H. Putter SH. Heisterkamp J.M.A. Lange F. Solf Particlede (2002) ArticleTitleA Bayesian approach to parameter estimation in HIV dynamical models Stat. Med. 21 2199–2214 Occurrence Handle10.1002/sim.1211 Occurrence Handle12210633 Occurrence Handle1:STN:280:DC%2BD38vkvF2ktg%3D%3D
G. Graham S. Gupta L. Aarons (2002) ArticleTitleDetermination of an optimal dosage regimen using a Bayesian decision analysis of efficacy and adverse effect data J. Pharmacokinet. Pharmacodyn. 29 67–88 Occurrence Handle10.1023/A:1015720718875 Occurrence Handle12194536 Occurrence Handle1:CAS:528:DC%2BD38XmslGlsr4%3D
WR. Gilds S. Richardson D.J. Spiegelhalter (1995) Markov Chain Monte Carlo in practice Chapman & Hall London
DJ. Lunn N. Best A. Thomas J. Wakefield D Spiegelhalter (2002) ArticleTitleBayesian analysis of population PK/PD models: general concepts and software J. Pharmacokinet Pharmacodyn. 29 271–307 Occurrence Handle10.1023/A:1020206907668 Occurrence Handle12449499 Occurrence Handle1:CAS:528:DC%2BD38XntFGrt7w%3D
S. Mu T.M. Ludden (2003) ArticleTitleEstimation of population pharmacokinetic parameters in the presence of non-compliance J. Pharmacokinet. Pharmacodyn. 30 53–81 Occurrence Handle10.1023/A:1023297426153 Occurrence Handle12800807
I.S. Nam. Propagation of information in pharmacokinetic and pharmacodynamic studies during drug development. PhD Thesis. Unversity of Manchester, Manchester, 2003
L. Aarons JW. Mandema M. Danhof (1991) ArticleTitleA population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat J. Pharmacokinet. Biopharm. 19 485–496 Occurrence Handle10.1007/BF01062959 Occurrence Handle1783988 Occurrence Handle1:CAS:528:DyaK38Xht1Sku7g%3D
JW. Mandema E. Tukker M. Danhof (1992) ArticleTitleIn vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazenil J Pharmacol. Exp. Ther. 260 36–44 Occurrence Handle1:CAS:528:DyaK38XnsFOhug%3D%3D
RJ. Muirhead (1982) Aspects of multivariate statistical theory Wiley New York
J. Wakefield N. Rahman (2000) ArticleTitleThe combination of population pharmacokinetics studies Biometrics 56 263–270 Occurrence Handle10.1111/j.0006-341X.2000.00263.x Occurrence Handle10783805 Occurrence Handle1:STN:280:DC%2BD3c3ks1agtw%3D%3D
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dokoumetzidis, A., Aarons, L. Propagation of Population Pharmacokinetic Information Using a Bayesian Approach: Comparison with Meta-Analysis. J Pharmacokinet Pharmacodyn 32, 401–418 (2005). https://doi.org/10.1007/s10928-005-0048-9
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10928-005-0048-9